{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:52:13Z","timestamp":1792183933385,"version":"4.4.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Diffuse tenosynovial giant cell tumor (DTGCT) is a locally aggressive benign tumor of the synovium. Patients often initially present with pain, stiffness, and swelling of the affected joint with varying levels of severity. Treatment traditionally involved surgical resection exclusively; however, this could be complicated by high disease recurrence rates. New research has introduced several targeted systemic therapies onto the market changing the treatment paradigm and necessitating a multidisciplinary treatment approach in specialized centers to optimize patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This review synthesizes the current literature on DTGCT including its pathophysiology, classification, diagnosis, and available treatment options. There is a particular focus on the newer systemic therapies available and how these medications may be used in conjunction with surgery to enhance disease control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>DTGCT most commonly affects young to middle-aged adults, with a slight female predominance, and is most frequently found in the knee. Arthroscopic and even open synovectomy can have disease recurrence rates exceeding 50%. Colony stimulating factor 1 (CSF1) receptor inhibitors have proven effective at symptom palliation and reducing tumor burden in approximately 40% of patients. While these medications improve the quality of life for patients with unresectable disease, they may also be effective in the neoadjuvant setting to downstage surgical approaches and possibly improve disease control in otherwise highly morbid cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Surgery alone, the traditional standard for DTGCT, is often insufficient due to high recurrence rates. Systemic therapies can restore function and improve quality of life in patients with advanced disease with rare\u2014but potentially serious\u2014adverse effects. Combining surgical resection with neoadjuvant CSF1R inhibition may provide superior outcomes. Further research is needed to refine the role of systemic agents and develop multidisciplinary protocols. Although initial symptoms often lead patients to community providers, optimal care for patients with DTGCT is best delivered at referral centers with dedicated musculoskeletal oncology programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence:<\/jats:title>\n                    <jats:p>\n                      <jats:underline>Level V<\/jats:underline>\n                      . See Instructions for Authors for a complete description of levels of evidence.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2106\/jbjs.oa.25.00313","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T19:02:07Z","timestamp":1768330927000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Current Treatment Strategies for Diffuse Tenosynovial Giant Cell Tumor: A Review of the Literature"],"prefix":"10.2106","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3731-7235","authenticated-orcid":false,"given":"Hannah","family":"Mosher","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8441-8460","authenticated-orcid":false,"given":"Kristen","family":"Dean","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8532-8261","authenticated-orcid":false,"given":"Gabrielle","family":"Meli","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7318-5847","authenticated-orcid":false,"given":"Jessyka","family":"Desrosiers","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, University of Miami Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2722-7080","authenticated-orcid":false,"given":"Brooke","family":"Crawford","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, University of Miami Miller School of Medicine, Miami, Florida"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4704-5161","authenticated-orcid":false,"given":"H. Thomas","family":"Temple","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, University of Miami Miller School of Medicine, Miami, Florida"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6916-8042","authenticated-orcid":false,"given":"Francis J","family":"Hornicek","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, University of Miami Miller School of Medicine, Miami, Florida"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida"},{"name":"Department of Pathology, Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0983-8016","authenticated-orcid":false,"given":"Emily","family":"Jonczak","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida"},{"name":"Department of Medicine, Division of Medical Oncology, Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3406-6705","authenticated-orcid":false,"given":"Emanuela","family":"Palmerini","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida"},{"name":"Department of Medicine, Division of Medical Oncology, Miller School of Medicine, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7487-6465","authenticated-orcid":false,"given":"Erik J.","family":"Geiger","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, University of Miami Miller School of Medicine, Miami, Florida"},{"name":"Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1]]},"reference":[{"issue":"2","key":"R1-20260113","doi-asserted-by":"crossref","first-page":"107953","DOI":"10.1016\/j.ejso.2024.107953","article-title":"Active surveillance of diffuse-type tenosynovial giant cell tumors: a retrospective, multicenter cohort study","volume":"50","author":"Spierenburg","year":"2024","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"R2-20260113","doi-asserted-by":"crossref","first-page":"e0260795","DOI":"10.1371\/journal.pone.0260795","article-title":"Treatment, recurrence rates and follow-up of Tenosynovial Giant Cell Tumor (TGCT) of the foot and ankle-A systematic review and meta-analysis","volume":"16","author":"Siegel","year":"2021","journal-title":"PLoS One"},{"issue":"1S","key":"R3-20260113","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.otsr.2016.11.002","article-title":"Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)","volume":"103","author":"Gouin","year":"2017","journal-title":"Orthop Traumatol Surg Res"},{"issue":"10","key":"R4-20260113","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3390\/medicina60101675","article-title":"Treatment modalities for refractory-recurrent Tenosynovial Giant Cell Tumor (TGCT): an update","volume":"60","author":"Dania","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"R5-20260113","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.3899\/jrheum.160816","article-title":"Tenosynovial giant cell tumor: incidence, prevalence, patient characteristics, and recurrence. A registry-based cohort study in Denmark","volume":"44","author":"Ehrenstein","year":"2017","journal-title":"J Rheumatol"},{"issue":"2","key":"R6-20260113","first-page":"413","article-title":"Giant cell tumor of tendon sheath, tenosynovial giant cell tumor, and pigmented villonodular synovitis: defining the presentation, surgical therapy and recurrence","volume":"7","author":"Martin","year":"2000","journal-title":"Oncol Rep"},{"key":"R7-20260113","doi-asserted-by":"crossref","first-page":"102904","DOI":"10.1016\/j.ctrv.2025.102904","article-title":"Therapeutic advances in tenosynovial giant cell tumor: targeting the CSF1\/CSF1R axis","volume":"134","author":"Assi","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"R8-20260113","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3233\/TUB-220005","article-title":"Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor","volume":"44","author":"Tap","year":"2022","journal-title":"Tumour Biol"},{"issue":"6","key":"R9-20260113","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1470-2045(19)30100-7","article-title":"Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study","volume":"20","author":"Mastboom","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"R10-20260113","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/CCO.0b013e328347e1e3","article-title":"Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis","volume":"23","author":"Ravi","year":"2011","journal-title":"Curr Opin Oncol"},{"issue":"2","key":"R11-20260113","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/os.13179","article-title":"A new simple and practical clinical classification for tenosynovial giant cell tumors of the knee","volume":"14","author":"Zheng","year":"2022","journal-title":"Orthop Surg"},{"key":"R13-20260113","doi-asserted-by":"crossref","first-page":"1012527","DOI":"10.3389\/fonc.2022.1012527","article-title":"Expanding the molecular spectrum of tenosynovial giant cell tumors","volume":"12","author":"Gauduchon","year":"2022","journal-title":"Front Oncol"},{"key":"R14-20260113","doi-asserted-by":"crossref","first-page":"820046","DOI":"10.3389\/fimmu.2022.820046","article-title":"Update on tenosynovial giant cell tumor, an inflammatory arthritis with neoplastic features","volume":"13","author":"Robert","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"R15-20260113","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13023-021-01820-6","article-title":"The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study","volume":"16","author":"Bernthal","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"R16-20260113","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13244-023-01367-z","article-title":"MRI of diffuse-type tenosynovial giant cell tumour in the knee: a guide for diagnosis and treatment response assessment","volume":"14","author":"Spierenburg","year":"2023","journal-title":"Insights into Imaging"},{"issue":"5","key":"R17-20260113","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1148\/rg.285085134","article-title":"Pigmented villonodular synovitis: radiologic-pathologic correlation","volume":"28","author":"Murphey","year":"2008","journal-title":"Radiographics"},{"issue":"11","key":"R18-20260113","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.acra.2023.01.012","article-title":"MRI prediction model for tenosynovial giant cell tumor with risk of diffuse-type","volume":"30","author":"Kim","year":"2023","journal-title":"Acad Radiol"},{"key":"R19-20260113","doi-asserted-by":"crossref","first-page":"109469","DOI":"10.1016\/j.ejrad.2020.109469","article-title":"Suspected intra-articular soft-tissue tumours and tumour-like lesions: performance of image-guided core needle biopsy","volume":"135","author":"Junaid","year":"2021","journal-title":"Eur J Radiol"},{"issue":"5","key":"R20-20260113","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00256-022-04094-6","article-title":"Image-guided synovial biopsy with a focus on neoplastic lesions","volume":"52","author":"Yip","year":"2023","journal-title":"Skeletal Radiol"},{"issue":"3","key":"R21-20260113","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.21873\/anticanres.17496","article-title":"Mismatch between preoperative MRI findings and postoperative histological results in the treatment of tenosynovial giant cell tumor","volume":"45","author":"Neugebauer","year":"2025","journal-title":"Anticancer Res"},{"issue":"1","key":"R22-20260113","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13000-022-01266-9","article-title":"Diagnostic utility of CSF1 immunohistochemistry in tenosynovial giant cell tumor for differentiating from giant cell-rich tumors and tumor-like lesions of bone and soft tissue","volume":"17","author":"Sugita","year":"2022","journal-title":"Diagn Pathol"},{"issue":"8","key":"R23-20260113","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/PAS.0b013e3181a6d86f","article-title":"Clusterin is expressed in normal synoviocytes and in tenosynovial giant cell tumors of localized and diffuse types: diagnostic and histogenetic implications","volume":"33","author":"Boland","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"R24-20260113","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41379-018-0129-0","article-title":"Malignant tenosynovial giant cell tumor: the true \u201cSynovial Sarcoma?\u201d A clinicopathologic, immunohistochemical, and molecular cytogenetic study of 10 cases, supporting origin from synoviocytes","volume":"32","author":"Al-Ibraheemi","year":"2019","journal-title":"Mod Pathol"},{"issue":"10","key":"R25-20260113","first-page":"939","article-title":"Tenosynovial giant cell tumors: evidence for a desmin-positive dendritic cell subpopulation","volume":"11","author":"Folpe","year":"1998","journal-title":"Mod Pathol"},{"issue":"22","key":"R26-20260113","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1158\/1078-0432.CCR-22-1898","article-title":"Interactions in CSF1-Driven tenosynovial giant cell tumors","volume":"28","author":"van Ijzendoorn","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"12","key":"R27-20260113","first-page":"e21.00217","article-title":"Arthroscopic versus open management of diffuse-type tenosynovial giant cell tumor of the knee: a meta-analysis of retrospective cohort studies","volume":"4","author":"Chandra","year":"2021","journal-title":"J Am Acad Orthop Surg"},{"issue":"11","key":"R28-20260113","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1007\/s11999-009-0922-7","article-title":"Outcomes after excision of pigmented villonodular synovitis of the knee","volume":"467","author":"Sharma","year":"2009","journal-title":"Clin Orthop Relat Res"},{"issue":"7","key":"R29-20260113","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.fas.2019.10.014","article-title":"Incomplete resection increases the risk of local recurrence and negatively affects functional outcome in patients with tenosynovial giant cell tumor of the hindfoot","volume":"26","author":"Tsukamoto","year":"2020","journal-title":"Foot Ankle Surg"},{"issue":"3","key":"R30-20260113","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s11999-012-2589-8","article-title":"Does combined open and arthroscopic synovectomy for diffuse PVNS of the knee improve recurrence rates?","volume":"471","author":"Colman","year":"2013","journal-title":"Clin Orthop Relat Res"},{"issue":"1","key":"R31-20260113","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00167-014-3375-9","article-title":"Combined arthroscopic and open synovectomy for diffuse pigmented villonodular synovitis of the knee","volume":"24","author":"Mollon","year":"2016","journal-title":"Knee Surg Sports Traumatol Arthrosc"},{"key":"R32-20260113","doi-asserted-by":"crossref","first-page":"102491","DOI":"10.1016\/j.ctrv.2022.102491","article-title":"Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts","volume":"112","author":"Stacchiotti","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"19","key":"R33-20260113","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1002\/cncr.26529","article-title":"Long\u2010term outcome of the treatment of high\u2010risk tenosynovial giant cell tumor\/pigmented villonodular synovitis with radiotherapy and surgery","volume":"118","author":"Griffin","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"R34-20260113","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0360-3016(95)00514-Y","article-title":"Outcome following radiation treatment for high-risk pigmented villonodular synovitis","volume":"32","author":"O'Sullivan","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"R35-20260113","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.3390\/cancers13153647","article-title":"Current concepts in the treatment of giant cell tumors of bone","volume":"13","author":"Tsukamoto","year":"2021","journal-title":"Cancers"},{"key":"R36-20260113","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2016.04.022","article-title":"Diffuse-type tenosynovial giant cell tumour: current treatment concepts and future perspectives","volume":"63","author":"Staals","year":"2016","journal-title":"Eur J Cancer"},{"issue":"10197","key":"R37-20260113","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet (London, England)"},{"key":"R38-20260113","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2022.06.028","article-title":"Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: long-term follow-up of nilotinib in TGCT","volume":"173","author":"Spierenburg","year":"2022","journal-title":"Eur J Cancer"},{"issue":"5","key":"R39-20260113","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S1470-2045(18)30143-8","article-title":"Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial","volume":"19","author":"Gelderblom","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"R40-20260113","doi-asserted-by":"crossref","first-page":"307","DOI":"10.56875\/2589-0646.1032","article-title":"Updates on the treatment of tenosynovial giant cell tumor","volume":"16","author":"Chan","year":"2023","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"6","key":"R41-20260113","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/cncr.26409","article-title":"Efficacy of imatinib mesylate for the treatment of locally advanced and\/or metastatic tenosynovial giant cell tumor\/pigmented villonodular synovitis","volume":"118","author":"Cassier","year":"2012","journal-title":"Cancer"},{"key":"R42-20260113","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.suronc.2020.08.030","article-title":"The effect of imatinib mesylate in diffuse-type tenosynovial giant cell tumours on MR imaging and PET-CT","volume":"35","author":"Mastboom","year":"2020","journal-title":"Surg Oncol"},{"issue":"16","key":"R43-20260113","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2217\/fon-2023-0363","article-title":"Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA","volume":"20","author":"Dharmani","year":"2024","journal-title":"Future Oncol (London, England)"},{"issue":"3","key":"R44-20260113","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s11427-024-2790-7","article-title":"Peficitinib suppresses diffuse-type tenosynovial giant cell tumor by targeting TYK2 and JAK\/STAT signaling","volume":"68","author":"Lu","year":"2025","journal-title":"Sci China. Life Sci"},{"issue":"4","key":"R45-20260113","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1093\/oncolo\/oyad282","article-title":"Real-world patient experience of pexidartinib for tenosynovial giant-cell tumor","volume":"29","author":"Lin","year":"2024","journal-title":"Oncologist"},{"issue":"4","key":"R46-20260113","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40487-024-00298-z","article-title":"Pexidartinib upfront in a case of tenosynovial giant cell tumor: proof of concept for a treatment paradigm shift","volume":"12","author":"Palmerini","year":"2024","journal-title":"Oncol Ther"},{"issue":"4","key":"R49-20260113","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/14737140.2025.2469755","article-title":"An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors","volume":"25","author":"Kisielewska","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10","key":"R50-20260113","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2217\/fon-2023-0238","article-title":"The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor","volume":"20","author":"Tap","year":"2024","journal-title":"Future Oncol (London, England)"},{"issue":"1","key":"R51-20260113","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jos.2022.10.016","article-title":"Use of neoadjuvant pexidartinib with limb salvage surgery for diffuse tenosynovial giant cell tumor: a case report","volume":"29","author":"Geiger","year":"2024","journal-title":"J Orthop Sci"},{"key":"R52-20260113","first-page":"7768764","article-title":"Complementary effects of surgery and pexidartinib in the management of patients with complex diffuse-tenosynovial giant cell tumor","volume":"2022","author":"Bernthal","year":"2022","journal-title":"Case Rep Orthop."}],"container-title":["JBJS Open Access"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.OA.25.00313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:23:43Z","timestamp":1787750623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.OA.25.00313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2106\/jbjs.oa.25.00313","relation":{},"ISSN":["2472-7245"],"issn-type":[{"value":"2472-7245","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}